Phase 1 trial of entinostat as monotherapy and combined with exemestane in Japanese patients with hormone receptor-positive advanced breast cancer

BACKGROUND: Entinostat is an oral inhibitor of class I histone deacetylases intended for endocrine therapy-resistant patients with hormone receptor-positive (HR+) advanced or metastatic breast cancer (BC). We examined the safety, efficacy, and pharmacokinetics of entinostat monotherapy and combined...

Descripción completa

Detalles Bibliográficos
Autores principales: Masuda, Norikazu, Tamura, Kenji, Yasojima, Hiroyuki, Shimomura, Akihiko, Sawaki, Masataka, Lee, Min-Jung, Yuno, Akira, Trepel, Jane, Kimura, Ryoko, Nishimura, Yozo, Saji, Shigehira, Iwata, Hiroji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611843/
https://www.ncbi.nlm.nih.gov/pubmed/34819039
http://dx.doi.org/10.1186/s12885-021-08973-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8611843/
https://www.ncbi.nlm.nih.gov/pubmed/34819039
http://dx.doi.org/10.1186/s12885-021-08973-4

Ejemplares similares